why choose us

First received: November 07, 2022

Clinical Trial: Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

Study Status: Completed

Recruit Status: RECRUITING

Condition: Juvenile Idiopathic Arthritis

Study Type: INTERVENTIONAL


Official Title: A Multicenter, Randomized Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Upadacitinib With a Tocilizumab Reference Arm in Subjects From 1 Year to Less Than 18 Years Old With

Brief Summary: Juvenile Idiopathic Arthritis (JIA) is the most common type of arthritis that affects children.The term "idiopathic" means "of unknown origin".It is a chronic (long-lasting) disease that causes swelling, warmth, and pain of one or more small joints.Systemic JIA ia a rare and serious form of JIA.Systemic" means it may affect not only the joints but other parts of the body, including the liver, lungs and heart.sJIA is more severe and can be more challenging to diagnose and treat than other…

Read more